References
- Anneken J, Gudelsky G. (2012). MDMA produces a delayed and sustained increase in the extracellular concentration of glutamate in the rat hippocampus. Neuropharmacology 63:1022–7
- Basilico L, Parolaro D, Rubino T, et al. (1992). Influence of omega-conotoxin on morphine analgesia and withdrawal syndrome in rats. Eur J Pharmacol 218:75–81
- Berman RF, Verweij BH, Muizelaar JP. (2000). Neurobehavioral protection by the neuronal calcium channel blocker Ziconotide in a model of traumatic diffuse brain injury in rats. J Neurosurg 93:821–8
- Bisaga A, Comer SD, Ward AS, et al. (2001). The NMDA antagonist memantine attenuates the expression of opioid physical dependence in human. Psychpharmacology (Berl) 151:1–10
- Bodnar RJ, Klein GE. (2005). Endogenous opiates and behavior: 2004. Peptides 26:2629–711
- Chahl LS. (1996). Opioids – mechanisms of action. Aust Prescr 19:63–5
- Choi DW, Maulucci-Gedde M, Kriegstein AR. (1987). Glutamate neurotoxicity in cortical cell culture. J Neurosci 7:357–68
- Chou WB, Zeng YM, Duan SM, et al. (2002). M2 muscarinic receptor of spinal cord mediated increase of nNOS expression in locus coeruleus during morphine withdrawal. Acta Pharmacol Sin 23:691–7
- Esmaeili-Mahani S, Fathi Y, Motamedi F, et al. (2008). L-type calcium channel blockade attenuates morphine withdrawal: in vivo interaction between L-type calcium channels and corticosterone. Horm Behav 53:351–7
- Hajhashemi V, Rabbani M, Asghari GR, Karami Saravi Z. (2004). Effects of Otostegia Persica (Burm.) Boiss onmorphine withdrawal syndrome in mice. Iranian J Pharm Res 3:171–5
- Lindsay H, Zhen Jin BS, Scott Bowersox S. (1999). The neuroprotective effects of intrathecal administration of the selective N-type calcium channel blocker ziconotide in a rat model of spinal ischemia. J Vas Surg 30:334–43
- McGivern JG. (2007). Ziconotide: a review of its pharmacology and use in the treatment of pain. Neuropsychiatr Dis Treat 3:69–85
- Mestre C, Pelissier T, Fialip J, et al. (1994). A method to perform direct transcutaneous intrathecal injection in rats. J Pharmacol Toxicol Methods 32:197–200
- O’ Brain CP. (2006). Drug addiction and drug abuse. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman & Gilman’s the pharmacological basis of therapeutics. New York: McGraw-Hill
- Perez-Pinzon MA, Yenari MA, Sun GH, et al. (1997). SNX-111, a novel, presynaptic N-type calcium channel antagonist, is neuroprotective against focal cerebral ischemia in rabbits. J Neurol Sci 153:25–31
- Peters J, Varies TJD. (2012). Glutamate mechanisms underlying opiate memories. Cold Spring Harb Perspect Med 9:1101–10
- Rubio M, Villain H, Docagne F, et al. (2011). Pharmacological activation/inhibition of the cannabinoid system affects alcohol withdrawal-induced neuronal hypersensitivity to excitotoxic insults. PLoS 6:23–90
- Skov M, Beck JC, de Kater AW, Shopp GM. (2007). Nonclinical safety of ziconotide: an intrathecal analgesic of a new pharmaceutical class. Int J Toxicol 26:411–21
- Tanganelli S, Antonelli T, Morari M, et al. (1991). Glutamate antagonists prevent morphine withdrawal in mice and guinea pigs. Neurosci Lett 122:270–2
- Twede V, Miljanich G, Olivera B, Bulaj G. (2009). Neuroprotective and cardioprotective conopeptides: An emerging class of drug leads. Curr Opin Drug Discov Devel 12:231–9
- Valentino K, Newcomb R, Gadbois T, et al. (1993). A selective N-type calcium channel antagonist protects against neuronal loss after global cerebral ischemia. Proc Natl Acad Sci 90:7894–7
- Valverde O, Roques BP. (1998). Cholecystokinin modulates the aversive component of morphine withdrawal syndrome in rats. Neurosci Lett 244:37–40
- Vaseghi G, Rabbani M, Hajhashemi V. (2012). The effect of nimodipine on memory impairment during spontaneous morphine withdrawal in mice: corticosterone interaction. Eur J Pharmacol 695:83–7
- Wang YX, Gao D, Pettus M, et al. (2000). Interaction of intrathecally administered ziconotide, a selective blocker of neuronal N-type voltage-sensitive calcium channels with morphine on nociception in rats. Pain 84:271–81
- Yenari MA, Palmer JT, Sun GH, et al. (1996). Time-course and treatment response with SNX-111, an N-type calcium channel blocker, in a rodent model of focal cerebral ischemia using diffusion-weighted MRI. Brain Res 739:36–45